GlaxoSmithKline LLC et al v. Teva Pharmaceuticals USA Inc.

Filing 191

REPORT AND RECOMMENDATION recommending DENYING D.I. 63 MOTION to Dismiss for Failure to State a Claim [DEFENDANT TEVA PHARMACEUTICALS USA, INC.'S MOTION TO DISMISS PLAINTIFFS' SECOND AMENDED COMPLAINT FOR FAILURE TO STATE A CLAIM] filed by Teva Pharmaceuticals USA Inc.. Please note that when filing Objections pursuant to Federal Rule of Civil Procedure 72(b)(2), briefing consists solely of the Objections (no longer than ten (10) pages) and the Response to the Objections (no longer than ten (10) pages). No further briefing shall be permitted with respect to objections without leave of the Court. Objections to R&R due by 8/8/2016. Signed by Judge Christopher J. Burke on 7/20/2016. (mlc)

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
GLAXOSMITHKLINE LLC and
SMITHKLINE BEECHAM (CORK)
LIMITED,

)
)
)
)
)
Plaintiffs,
)
v.
)
)
TEVA PHARMACEUTICALS USA, INC., )
)
Defendant.
)

Civil Action No. 14-878-LPS-CJB

REPORT AND RECOMMENDATION

Presently pending in this patent infringement case is Defendant Teva Pharmaceuticals
USA, Inc.'s ("Defendant" or "Teva") motion (the "Motion") seeking to dismiss, pursuant to
Federal Rule of Civil Procedure 12(b)(6), Plaintiffs GlaxoSmithKline LLC and SmithKline
Beecham (Cork) Limited's (collectively, "GSK") induced infringement claim relating to the
period between January 2008 and May 2011 ("the pre-May 2011 period") in GSK's Second
Amended Complaint ("SAC"). (D.I. 63) For the reasons set forth below, the Court recommends
that Teva's Motion be DENIED.
I.

BACKGROUND 1
A.

Factual Background
1.

Approval of Carvedilol by the United States Food and Drug
Administration ("FDA") and the '069 Patent

In this Report and Recommendation, the Court will assume familiarity with the
facts and procedural history detailed in a prior opinion in this action, GlaxoSmithKline LLC v.
Glenmark Generics, Inc., USA, No. Civ.A. 14-877-LPS, Civ.A. 14-878-LPS, 2015 WL 3793757
(D. Del. Apr. 22, 2015), report and recommendation adopted, 2015 WL 4730913 (D. Del. Aug.
10, 2015).

Carvedilol is a drug belonging to a class of chemical compounds known as beta blockers,
which may be used to treat, inter alia, hypertension. (D.I. 60 (hereinafter, "SAC") at ,-r 8) In
1993, GSK filed New Drug Application (''NDA") No. 20-297 on carvedilol tablets to manage
hypertension, and it received FDA approval to market the drug for this purpose in 1995. (Id.)
However, due to the crowded market for hypertension treatment, and due to clinical studies
indicating that long-term administration of carvedilol decreased the risk of mortality in patients
with congestive heart failure ("CHF"), GSK held off on launching the drug in the United States
at that time. (Id.) Instead, it worked to obtain FDA approval to market carvedilol for the
treatment of CHF. (Id.)
CHF is a chronic clinical condition that occurs when the diseased heart's ability to pump
blood has been reduced, and the heart is therefore unable to deliver sufficient oxygen to meet the
body's needs. (Id. at ,-r 9) The condition is the end stage of the cardiovascular disease
continuum-a chain of events set off by several cardiovascular risk factors such as diabetes,
hypertension and obesity. (Id. at ,-r 10) If CHF is left untreated, it will lead to end stage heart
failure and death. (Id. (citation omitted))
In June 1995, GSK and its research partner filed a patent application directed to a method
of using carvedilol to decrease the risk of mortality caused by CHF, which later issued in June
1998 as U.S. Patent No. 5,760,069 (the '"069 patent"). (Id. at ,-r 35) The '069 patent is entitled
"'Method of Treatment for Decreasing Mortality Resulting from Congestive Heart Failure."'
(Id.) In 1997, GSK's carvedilol tablets became the first beta blocker to receive FDA approval for

the treatment of CHF-specifically, for the treatment of mild-to-moderate CHF of ischemic or
cardiomyopathic origin, in conjunction with digitalis, diuretics, and ACE inhibitor, to reduce the

2

progression of disease as evidenced by cardiovascular death, cardiovascular hospitalization, or
the need to adjust other CHF medications. (Id. at if 21) After that, GSK began marketing and
selling its carvedilol tablets under the brand name COREG® ("COREG"), promoting only the
CHF indication. (Id. at if 22) In 2001, the FDA approved carvedilol for the treatment of mild-tosevere CHF of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE
inhibitors and digitalis, to increase survival and also to reduce the risk of hospitalization due to
CHF. (Id. at if 27)
Despite these FDA-approved indications, there were patients with CHF, or that were
likely to develop CHF, who had recently experienced a myocardial infarction (i.e., a heart attack)
and who could not receive COREG. (Id. at if 28) This was because the drug was not approved
for use by a person who had recently had a heart attack, due to concerns that such a person's
condition could worsen were the drug administered in that circumstance. (Id.) GSK hoped to
expand the use of COREG to include these persons, and it conducted two studies in that regard:
the Carvedilol Heart Attack Pilot Study ("CHAPS") and the CAPRICORN study. (Id. at iii! 2930) In 2003, in light of positive results from these studies, carvedilol received FDA approval for
the treatment ofleft ventricular dysfunction ("LVD") following myocardial infarction ("post-MI
LVD") in clinically stable patients. (Id. at ml 29-31)
GSK's label for COREG has three indications (the first two of which are most relevant
for purposes of this Motion):
1 INDICATIONS AND USAGE
1.1 Heart Failure
COREG® is indicated for the treatment of mild-to-severe chronic
3

heart failure of ischemic or cardiomyopathic origin, usually in
addition to diuretics, ACE inhibitors, and digitalis, to increase
survival and, also, to reduce the risk of hospitalization [see Drug
Interactions (7.4) and Clinical Studies (14.1)].

1.2 Left Ventricular Dysfunction Following Myocardial
Infarction
COREG is indicated to reduce cardiovascular mortality in
clinically stable patients who have survived the acute phase of a
myocardial infarction and have a left ventricular ejection fraction
of ~:;40% (with or without symptomatic heart failure) [see Clinical
Studies (14.2)}.

1.3 Hypertension
COREG is indicated for the management of essential hypertension

(SAC, ex. F (emphasis in original))

2.

The Hatch-Waxman Act, FDA Requirements and the Orange Book

The Hatch-Waxman Act, codified as amended at 21 U.S.C. § 355 and 35 U.S.C. §§ 156,
271 and 282, strikes a balance between the competing policy interests of"(l) inducing
pioneering research and development of new drugs and (2) enabling competitors to bring lowcost, generic copies of those drugs to market." Andrx Pharms., Inc. v. Biovail Corp., 276 F.3d
1368, 1370-71 (Fed. Cir. 2002). A brand name drug manufacturer seeking FDA approval for a
drug must submit an NDA that includes, inter alia, a statement of the drug's components and
proposed labeling describing the uses for which the drug may be marketed. 21 U.S.C. §
355(b)(l); Caraco Pharms. Labs., Ltd. v. Novo NordiskA/S, 132 S. Ct. 1670, 1676 (2012). A
brand name drug may be approved for multiple methods of use-either to treat different
conditions or to treat one condition in different ways. Caraco, 132 S. Ct. at 1676. Once a drug

4

has been approved by the FDA, another company may seek permission to launch a generic
version of the drug by filing an Abbreviated New Drug Application ("ANDA") with the FDA.
21 U.S.C. § 355(j); Caraco, 132 S. Ct. at 1676. The ANDA process circumvents the lengthy
approval scheme in place for ND As by permitting generic manufacturers to depend on the safety
and efficacy studies completed for the previously-approved drug, so long as there is
bioequivalency between the generic drug and the previously-approved drug. Bayer Schering

PharmaAGv. Lupin, Ltd., 676 F.3d 1316, 1318 (Fed. Cir. 2012).
When evaluating an ANDA seeking to market a generic drug, the FDA considers whether
the proposed drug would infringe a patent held by the brand name manufacturer of the drug.

Caraco, 132 S. Ct. at 1675. "[T]he Hatch-Waxman Act creates a mechanism that allows for
prompt judicial determination of whether the ANDA applicant's drug or method of using the
drug infringes a valid patent." Bayer, 676 F.3d at 1318. In line with its goals of protecting
patentees and facilitating approval of generic drugs, the Act dictates that a brand name
manufacturer's NDA must identify specific patent information with respect to which a claim of
patent infringement could "reasonably be asserted ... [due to] the ... use ... of the drug." 21
U.S.C. § 355(b)(l)(G); see also Bayer, 676 F.3d at 1318. This requirement also applies to
patents that issue subsequent to final approval of the NDA. 21 U.S.C. § 355(c)(2); see also

Allergan, Inc. v. Alcon Labs., Inc., 324 F.3d 1322, 1325 (Fed. Cir. 2003). The FDA lists these
identified patents in a publication called Approved Drug Products with Therapeutic Equivalence

Evaluations, universally referred to in the industry as the "Orange Book." Bayer, 676 F.3d at
1318.

If the brand name manufacturer holds a method of use patent that gives it exclusive rights

5

over a particular method of using the drug subject to the NDA, FDA regulations require it to: (1)
indicate "[w ]hether the patent claims one or more methods of using the drug product for which
use approval is being sought and a description of each pending method of use or related
indication and related patent claim of the patent being submitted" and (2) provide
"[i]dentification of the specific section of the proposed labeling for the drug product that
corresponds to the method of use claimed by the patent submitted[.]" 21 C.F .R. §
314.53(c)(2)(0)(i)(l)-(2). The manufacturer's descriptions of the method-of-use patents are
referred to as ''use codes." Caraco, 132 S. Ct. at 1676. The FDA then publishes these use codes,
along with the corresponding patent numbers and expiration dates, in the Orange Book. Id.

3.

Teva's ANDA and the '000 Patent

In March 2002, Teva filed ANDA No. 76-373 seeking to market generic carvedilol

tablets. (SAC at ii 47) At this time, the Orange Book listed the '069 patent for COREG. (Id. at ii
48) A few months later, Teva notified GSK that its ANDA included a Paragraph IV certification
asserting that the '069 patent was invalid and unenforceable. (Id. at ii 49) In November 2003, the
then-owner of the '069 patent instituted a reissue proceeding before the United States Patent and
Trademark Office ("PTO"). (Id. at ii 36) In January 2008, the '069 patent reissued as United
States Patent No. RE40,000 (the '"000 patent"), entitled "'Method of Treatment for Decreasing
Mortality Resulting from Congestive Heart Failure.'" (Id.) Claim 1 of the '000 patent recites:
1. A method of decreasing mortality caused by congestive
heart failure in a patient in need thereof which comprises
administering a therapeutically acceptable amount of
carvedilol in conjunction with one or more other therapeutic
agents, said agents being selected from the group consisting
of an angiotensin converting enzyme inhibitor (ACE), a
diuretic, and digoxin,

6

wherein the administering comprises administering to said
patient daily maintenance dosages for a maintenance
period to decrease a risk of mortality caused by congestive
heart failure, and said maintenance period is greater than
six months.
(SAC, ex. E ("'000 Patent"), col. 8:30-40 (emphasis in original, representing additions to the
claim during the reissue proceeding)) The '000 patent expired on June 7, 2015. (Id. at ii 40)
After the '000 patent issued, GSK "submitted patent information regarding the '000 patent
and requested the withdrawal of the '069 patent from the Orange Book." (Id.) Specifically, GSK
identified "decreasing mortality caused by congestive heart failure" as being covered by the '000
patent. (Id.) Accordingly, in February 2008, the '000 patent was listed in the Orange Book with
patent use code U-233 ("decreasing mortality caused by congestive heart failure"). (Id.)

4.

Approval of Teva's Product and its Product Label

An ANDA applicant is required to consult the Orange Book and take action relating to all

pertinent patents. Bayer, 676 F.3d at 1318. If a patent listed in the Orange Book is a method-ofuse patent, like the '000 patent, "the generic applicant can attempt to seek FDA approval to label
its drug only for uses not covered by the patent" by submitting a "section viii statement" with its
ANDA. (SAC at ii 45); see also 21 U.S.C. § 355G)(2)(A)(viii); Bayer, 676 F.3d at 1318. These
statements are referred to as "carve-outs" or "section viii carve-outs" because they are said to
"limit[] the scope of the generic manufacture[r]'s ANDA to approved indications that are not
claimed by valid patents listed in the Orange Book." Astrazeneca Pharms. LP v. Apotex Corp.,
Civil No. 10-338 (RBK/KW), 2010 WL 5376310, at *2 (D. Del. Dec. 22, 2010); see also Bayer,

7

676 F.3d at 1318. 2 This process is meant to ensure that "one patented use will not foreclose
marketing a generic drug for other unpatented ones." Caraco, 132 S. Ct. at 1682. If the section
viii carve-out is approved, "the FDA will require the generic company to duplicate only the
portions of the branded drug's label not protected by the applicable method-of-use patent, as
identified in the patent use code." (SAC at if 45); see also AstraZeneca LP v. Apotex, Inc., 633
F.3d 1042, 1046 (Fed. Cir. 2010) ("AstraZeneca 2010"). 3 The FDA takes the use code at face
value-it does not independently assess the patent's scope or otherwise look beyond the use code
description written by the brand. Caraco, 132 S. Ct. at 1677. The FDA has described its own
role with respect to patent listing as "'ministerial[,]"' id. (internal citation omitted), as it "is not
the arbiter of patent infringement issues[,]" AstraZeneca 2010, 633 F.3d at 1061. Section viii
statements do not require notice to the patent-holder and therefore foreclose automatic initiation
of patent infringement litigation. In re Gabapentin Patent Litig., 649 F. Supp. 2d 340, 345 n.7

2

The section viii carve-out stands in contrast to a paragraph IV certification, which
is a generic drug manufacturer's other option when the Orange Books lists a method-of-use
patent set to expire after the release of the generic drug. Caraco, 132 S. Ct. at 1676-77. An
ANDA applicant should file a paragraph IV certification (instead of a section viii carve-out)
when it is "seeking approval for exactly the same labeling as that in the NDA for which the
patent was submitted." Bayer, 676 F.3d at 1318 (quoting Applications for FDA Approval to
Market a New Drug, 68 Fed. Reg. 36,676, 36,682 (June 18, 2003)). Such a certification states
that a listed patent "is invalid or will not be infringed by the manufacture, use, or sale of the
[generic] drug[,]" 21 U.S.C. § 355(j)(2)(A)(vii)(IV), and pursuant to 35 U.S.C. § 271(e)(2)(A),
the filing of a paragraph IV certification is treated as itself an act of infringement that gives the
brand name manufacturer an immediate right to file suit, see Caraco, 132 S. Ct. at 1677.
3

However, one court has noted that the "FDA has consistently determined that it
can approve [section viii] AND As for broad, general indications that may partially overlap with a
protected method of use, so long as any express references to the protected use are omitted from
the labeling." Hospira, Inc. v. Burwell, No. GJH-14-02662, 2014 WL 4406901, at *14 (D. Md.
Sept. 5, 2014) (internal quotation marks and citation omitted).

8

(D.N.J. 2009).
Although Teva had originally submitted a Paragraph IV certification asserting that the
'069 Patent was invalid, in or about August 2007, Teva amended its ANDA to a section viii
statement, and did not include in its proposed label those portions of GSK' s label directly
"relating to the CHF indication." (SAC at iMf 49-51; see also D.I. 69 at 3) Teva received FDA
approval for its generic version of carvedilol on or about September 5, 2007, and until May 2011,
the label for its generic carvedilol tablets "carved out" the CHF indication. (SAC at iii! 51, 53 &
ex. J; D.I. 64 at 7)4

5.

The Orange Book and an "AB Rating" 5

The Orange Book also contains a coding system to identify products that are considered
to be therapeutically equivalent to other pharmaceutically equivalent products. (D.I. 65, ex. B at
xiii) One such code is an "AB rating." (Id.) The Orange Book states explicitly that when a
generic drug product is "AB-rated" or has an "AB rating[,]" that means that the product is the
therapeutic equivalent to a branded drug product only if the two are "pharmaceutical equivalents
and if they can be expected to have the same clinical effect and safety profile when administered
to patients under the conditions specified in the labeling" of the generic product. (Id. at vii; see

4

In May 2011, Teva amended its label to fully conform with GSK's label for

COREG, such that Teva's label now expressly included the CHF indication. (SAC at if 53 & ex.
G) This time period is not relevant for purposes ofTeva's Motion.
To the extent the information in this subsection is not contained in the SAC itself,
it comes from the 2009 print version of the Orange Book (the version issued the year after the
patent-in-suit was issued); excerpts from this version of the Orange Book were attached to a
declaration filed by Teva in conjunction with the instant Motion. (D.I. 65, ex. B) The Court can
consider the content of the Orange Book in resolving the Motion because it is expressly referred
to throughout the SAC and is integral to GSK's allegations. See In re Burlington Coat Factory
Sec. Litig., 114 F.3d 1410, 1426 (3d Cir. 1997).
9

also SAC at iJ 66) The Orange Book also states that "[t]here may be labeling differences among
pharmaceutically equivalent products that require attention on the part of the health professional"
and that "[a]n FDA evaluation that [two] such [pharmaceutically equivalent] products are
therapeutically equivalent is applicable only when each product is reconstituted, stored, and used
under the conditions specified in the labeling of that product." (D.I. 65, ex.Bat xiv)

B.

Procedural Background

On July 3, 2014, GSK commenced this action, as well as a related action against
Glenmark Pharmaceuticals Inc., USA ("Glenmark"), GlaxoSmithKline LLC v. Glenmark
Pharmaceuticals Inc., USA, Civil Action No. 14-877-LPS-CJB. In these actions, GSK brought
claims of indirect infringement (one count of induced infringement and one count of contributory
infringement) against Teva and Glenmark (collectively, "Defendants") concerning the '000
patent. (Civil Action No. 14-877-LPS-CJB, D.I. 1; Civil Action No. 14-878-LPS-CJB, D.I. 1)
Glenmark and Teva moved to dismiss the complaints, (Civil Action No. 14-877-LPS-CJB, D.I.
10; Civil Action No. 14-878-LPS-CJB, D.I. 10), and in response, GSK filed a First Amended
Complaint ("FAC") in each action, (Civil Action No. 14-877-LPS-CJB, D.I. 14; Civil Action No.
14-878-LPS-CJB, D.I. 16). On October 16, 2014, ChiefJudge Leonard P. Stark referred these
cases to the Court to hear and resolve all pretrial matters, up to and including the resolution of
case-dispositive motions. (Civil Action No. 14-877-LPS-CJB, D.I. 16; Civil Action No. 14-878LPS-CJB, D.I. 18)
In lieu of filing Answers to the FACs, Glenmark and Teva moved to dismiss GSK's
FACs in their entirety (i.e., both the induced infringement and contributory infringement counts),
pursuant to Federal Rule of Civil Procedure 12(b)(6). (Civil Action No. 14-877-LPS-CJB, D.I.
10

18; Civil Action No. 14-878-LPS-CJB, D.I. 20) 6 The Court thereafter issued a Report and
Recommendation regarding the motions to dismiss, which recommended: (1) grant of the
motions to dismiss as to GSK's claims regarding induced infringement during the time periods
where the CHF indication was not on Defendants' labels, with leave to amend; (2) denial of the
motions as to GSK's claims regarding induced infringement during the time periods where the
CHF indication was on Defendants' labels; and (3) denial of the motions as to GSK's claims for
contributory infringement. (Civil Action No. 14-877-LPS-CJB, D.I. 38; Civil Action No. 14878-LPS-CJB, D.I. 39) The District Court later adopted the Report and Recommendation in its
entirety, over Defendants' objections. (Civil Action No. 14-877-LPS-CJB, D.I. 54; Civil Action
No. 14-878-LPS-CJB, D.I. 55)
GSK then filed its SAC in this action. (D.I. 60) In lieu of filing an Answer, on
September 14, 2015, Teva filed the instant Motion, seeking dismissal of GSK's claims for
inducement of infringement for the pre-May 2011 time period (i.e., when Teva's label carved out
the CHF indication). (D.I. 63) 7 After Teva's Motion was fully briefed, (D.I. 70), the Court held
oral argument regarding the Motion on March 1, 2016, (D.I. 132 (hereinafter, "Tr.")). Following

6

As was the case with Teva, when Glenmark's generic carvedilol tablets launched
in September 2007, Glenmark's label carved out the CHF indication. (Civil Action No. 14-877LPS-CJB, D.I. 59 at if 49) However, it is alleged that between about August 2009 and about
August 2010, Glenmark revised its label for generic carvedilol tablets to fully conform with and
be identical (for all relevant purposes) to GSK's label for COREG, such that the label expressly
included the CHF indication. (Id. at iril 51-52 & ex. G) Thereafter, it appears that Glenmark
switched back to the version of the label that it had utilized prior to about August 2009. (Id. at iii!
52, 59)
7

Teva later filed an Answer to the SAC, (D.I. 105), in which it noted that the
Answer was being "submitted subject to and without intending to waive Teva's [M]otion[,]"
(id. at 1).
11

oral argument, GSK submitted a supplemental letter brief on March 3, 2016. (D.I. 124)
Meanwhile, in April 2015, with Defendants' motions to dismiss the FACs then pending,
the Court entered a Scheduling Order governing these related cases. (Civil Action No. 14-877LPS-CJB, D.I. 37; Civil Action No. 14-878-LPS-CJB, D.I. 38) Discovery has been ongoing,
with fact discovery having been completed on July 1, 2016. (Civil Action No. 14-877-LPS-CJB,
D.I. 121; Civil Action No. 14-878-LPS-CJB, D.I. 151) A five-day trial is scheduled to begin on
June 12, 2017. (Civil Action No. 14-877-LPS-CJB, D.I. 37; Civil Action No. 14-878-LPS-CJB,
D.I. 38)

II.

LEGAL STAND ARDS
A.

Motion to Dismiss

The sufficiency of pleadings for non-fraud cases is governed by Federal Rule of Civil
Procedure 8, which requires "a short and plain statement of the claim showing that the pleader is
entitled to relief[.]" Fed. R. Civ. P. 8(a)(2). When presented with a Rule 12(b)(6) motion to
dismiss for failure to state a claim, a court conducts a two-part analysis. Fowler v. UPMC
Shadyside, 578 F.3d 203, 210 (3d Cir. 2009). First, the court separates the factual and legal

elements of a claim, accepting "all of the complaint's well-pleaded facts as true, but
[disregarding] any legal conclusions." Id. at 210-11. Second, the court determines "whether the
facts alleged in the complaint are sufficient to show that the plaintiff has a 'plausible claim for
relief."' Id. at 211 (quoting Ashcroft v. Iqbal, 556 U.S. 662, 679 (2009)). "A claim has facial
plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable
inference that the defendant is liable for the misconduct alleged." Iqbal, 556 U.S. at 678 (citing
Bell Atl. Corp. v. Twombly, 550 U.S. 544, 556 (2007)). In assessing the plausibility of a claim,

12

the court must "accept all factual allegations as true, construe the complaint in the light most
favorable to the plaintiff, and determine whether, under any reasonable reading of the complaint,
the plaintiff may be entitled to relief." Fowler, 578 F.3d at 210 (quoting Phillips v. Cnty. of

Allegheny, 515 F.3d 224, 233 (3d Cir. 2008)).

B.

Induced Infringement

Pursuant to 35 U.S.C. § 271(b), "[w]hoever actively induces infringement of a
patent shall be liable as an infringer." In order to prove induced infringement, the patentee "must
show direct infringement, and that the alleged infringer knowingly induced infringement and
possessed specific intent to encourage another's infringement." Toshiba Corp. v. Imation Corp.,
681F.3d1358, 1363 (Fed. Cir. 2012) (quoting i4i Ltd. P'ship v. Microsoft Corp., 598 F.3d 831,
851 (Fed. Cir. 2010)); Symantec Corp. v. Comput. Assocs. Int'/, Inc., 522 F.3d 1279, 1292-93
(Fed. Cir. 2008) ("Thus, 'inducement requires evidence of culpable conduct, directed to

encouraging another's infringement, not merely that the inducer had knowledge of the direct
infringer's activities."') (emphasis added) (citation omitted). Moreover, the United States Court
of Appeals for the Federal Circuit has recognized that "mere knowledge of possible infringement
by others does not amount to inducement; specific intent and action to induce infringement must
be proven." Warner-Lambert Co. v. Apotex Corp., 316 F.3d 1348, 1364 (Fed. Cir. 2003)
(emphasis added); see also Novartis Pharms., Corp. v. Wockhardt USA LLC, Civil Action No.
12-cv-3967, 2013 WL 5770539, at *9 (D.N.J. Oct. 23, 2013) (noting that inducement involves
the taking of '"affirmative steps"') (internal citations omitted).
To survive Teva's Motion, then, GSK's SAC must contain facts that make out a plausible
claim of inducement as delineated above: "facts plausibly showing that [Teva] specifically

13

intended [third parties] to infringe the ['000 patent] and knew that the [third party's] acts
constituted infringement." In re Bill ofLading Transmission & Processing Sys. Patent Litig.,
681 F.3d 1323, 1339 (Fed. Cir. 2012). "This does not mean, however, that [GSK] must prove its
case at the pleading stage." Id. (citations omitted).

III.

DISCUSSION
Before assessing the sufficiency of GSK's current claim for induced infringement during

the pre-May 2011 time period, the Court offers a brief review of its reasoning for dismissing
GSK's prior allegations directed to this claim. GlaxoSmithKline LLC v. Glenmark Generics Inc.,
USA, No. Civ.A. 14-877-LPS, Civ.A. 14-878-LPS, 2015 WL 3793757 (D. Del. Apr. 22, 2015)
("GlaxoSmithKline I"), report and recommendation adopted, 2015 WL 4730913 (D. Del. Aug.

10, 2015). There, GSK had pointed to two paragraphs in its FAC as providing the requisite
factual specificity in support of its claim:
55. In addition, even prior to its labeling change, [Teva] caused its
generic carvedilol ... tablets to be listed in the Orange Book with a
therapeutic equivalence rating of "AB," which indicates that its
generic copies are considered therapeutically equivalent to
COREG® on all indications approved for the generic drug. On
information and belief, since the approval of its ANDA ... [Teva}
has actively promoted the "AB" rating of its generic carvedilol
tablets and marketed them as therapeutically equivalent to and
fully substitutable for GSK 's COREG® tablets indicated for
treatment of CHF. Although the Orange Book states explicitly that
an AB rating is limited to what is on the generic's approved label .
. . [Teva] never informed the public that its generic carvedilol was
not approved by the FDA for the CHF indication when it touted its
generic copy as AB-rated and fully substitutable for COREG®.
56. On information and belief, [Teva] knew that when an ABrated generic drug is available, many states and/or third party
payers of prescription drugs (e.g., health insurance plans, Medicare
and Medicaid programs) have adopted policies to encourage or
14

require the substitution of the AB-rated generic drugs for the
branded drugs, regardless of whether the generic drug label
includes all the indications contained in the branded drug label.
[Teva] also knew that unless informed otherwise, the market would
assume that, like most-AB-rated generic drugs, [Teva's] generic
carvedilol tablets were labeled identically to COREG® and
included the CHF indication. As a result, by promoting its generic
carvedilol tablets as AB-rated and fully substitutable for COREG®
without informing the market that its generic carvedilol tablets
were not approved for the CHF indication, [Teva] knew and
intended that its generic carvedilol tablets would be substituted for
COREG® for patients prescribed the drug for treatment of
congestive heart failure in the direct infringement of the '000
patent.
GlaxoSmithKline I, 2015 WL 3793757, at *4-5 (quoting D.I. 16

at~

55-56) (emphasis in

opinion, but not contained in the text of the FAC itself). While GSK asserted that the sentences
rendered in italics above made its inducement claims plausible, the Court disagreed. Instead, the
Court explained that "these key sentences suffer from a particular lack of any meaningful factual
content." Id. at *6. For instance, the Court noted that the sentences were silent as to "[ w ]hat
type of 'market[ing]' and 'promoting' [was Teva] alleged to have engaged in that gives rise to
the claim?" Id.
GSK now asserts that the allegations of its SAC "answer[] this question in spades." (D .I.
69 at 10) Teva disagrees, arguing that GSK's SAC "has not cured the defects" of GSK's prior
complaint. (D.I. 64 at 19) More specifically, Teva argues that GSK has failed to plausibly allege
that Teva possessed the specific intent to induce infringement in the relevant time period, or
plausibly allege that Teva knew that infringement by third parties (here, medical professionals
and/or patients) was occurring in the time period. (D.I. 64)
In explaining why it has sufficiently articulated a plausible claim, GSK points to two

15

primary aspects of the SAC. The first is the SAC's allegations regarding certain ways in which
Teva actively promoted its generic carvedilol tablets (i.e., by publicizing the drug's "AB rating"
and by disseminating certain press releases), both prior to and during the relevant time period.
(D.1. 69 at 1-2) The second relates to the explicit contents ofTeva's carve-out label. (Id.) While
keeping in mind that GSK' s theory of inducement is based on "the totality" of its allegations,
(see, e.g., Tr. at 56-58), for ease of discussion, the Court will analyze these two different sets of
allegations in turn. After doing so, the Court will also touch on some additional allegations in
the SAC that, in the Court's view, further bolster GSK's claim.
1.

Teva's Active Promotion of its Generic Carvedilol Tablets

In the SAC, GSK includes a number of allegations regarding certain ways in which Teva

actively promoted its generic carvedilol tablets prior to and during the relevant time period:
62 .... Teva caused its generic carvedilol 3.125 mg, 6.25 mg, 12.5
mg and 25 mg tablets to be listed in the Orange Book with a
therapeutic equivalence rating of "AB," which indicates that its
generic copies are considered therapeutically equivalent to
COREG® on all indications approved for the generic drug. On
information and belief, since the approval of its ANDA No. 76-373,
Teva has actively promoted on its website and other marketing
materials the "AB" rating of its generic carvedilol tablets and
marketed them as therapeutically equivalent to and fully
substitutable for GSK' s COREG® tablets indicated for treatment of
CHF.
63. For example, Teva's June 9, 2004 press release announcing the
tentative approval of its generic carvedilol tablets states, "Carvedilol
Tablets are the AB-rated generic equivalent of GlaxoSmithKline's
COREG® Tablets and are indicated for treatment of heart failure
and hypertension." [] Teva's press release stated that COREG®'s
annual sales were approximately $670 million. [] Those sales, of
course, included sales used to treat patients with CHF symptoms.
64. On September 6, 2007, Teva announced final FDA approval for
16

its generic version of GSK's COREG® tablets and that COREG®'s
U.S. sales were approximately $1.7 billion annually. [] Again, the
sales number included sales of COREG® used to treat patients
suffering from CHF symptoms.
65. On information and belief, Teva registered its generic
Carvedilol Tablets with data aggregators (e.g., Red Book) as ABrated to COREG®. And Teva's Product Catalog,[ 8] which is
available on Teva's website, has identified Teva's Carvedilol
Tablets as "AB Rated and bioequivalent to COREG® Tablets."
66. Although the Orange Book states explicitly that an AB rating is
limited to what is on the generic's approved label ... Teva never
informed the public that its generic carvedilol was not approved by
the FDA for the CHF indication when it touted its generic copy as
AB-rated and fully substitutable for COREG®.
67. On information and belief, Teva knew that when an AB-rated
generic drug is available, many states and/or third party payers of
prescription drugs (e.g., health insurance plans, Medicare and
Medicaid programs) have adopted policies to encourage or require
the substitution of the AB-rated generic drugs for the branded drugs,
regardless of whether the generic drug label includes all the
indications contained in the branded drug label. Teva also knew
that unless informed otherwise, the market would assume that, like
most AB-rated generic drugs, Teva's generic carvedilol tablets were
labeled identically to COREG® and included the CHF indication.
As a result, by promoting its generic carvedilol tablets as AB-rated
and fully substitutable for COREG® without informing the market
that its generic carvedilol tablets were not approved for the CHF
indication, Teva knew and intended that its generic carvedilol
tablets would be substituted for COREG® for patients prescribed
the drug for treatment of CHF resulting in the direct infringement of
the '000 patent.
(SAC

at~

62-67 (internal citations omitted) (emphasis in original)) These allegations raise a

With regard to the reference to Teva's Product Catalog, that catalog also notes
that the "AB" code and other similar codes are "published in FDA's Orange Book[.]" (D.I. 65,
ex. C) As is further noted below, the Orange Book, in turn, explains that a generic drug product
is the therapeutic equivalent of a branded drug only for those uses listed on the generic product's
label. (D .I. 64 at 13 n. 7)
17

few different issues, which the Court will assess below.

a.

The "AB rating"

As it did when addressing Defendants' motions to dismiss the FAC, here again GSK
seems to suggest that alleging the mere fact that Teva promoted its drug as "AB rated" to
COREG should be enough to set out a plausible claim for inducement, given the way some in the
market can sometimes misperceive what it means for a drug to be "AB-rated" to another drug.
(D.I. 69 at 10-12)9 In dismissing GSK's induced infringement claim in the FAC for the pre-May
2011 time period, the Court explained its view as to why simply making the bald statement that
Teva was actively "promoting its generic carvedilol tablets as AB-rated and fully substitutable
for" COREG-standing alone-was not sufficient to plausibly allege Teva's intent to induce
infringement. To that end, the Court stated that "[i]t is hard to conclude that Defendants'
obtaining an AB rating in the Orange Book for their product, standing alone, could amount to
sufficient 'action' to encourage infringement of a patented use [i.e., the CHF indication] not

listed on their label-when the Orange Book affirmatively instructs that a generic drug product is
the therapeutic equivalent of a branded drug only for those uses listed on the Defendants' label."

GlaxoSmithKline I, 2015 WL 3793757, at *5 (emphasis in original).
The Court remains unconvinced that this conclusion was incorrect. "Obtaining [an] AB
rating is a perfectly lawful step, created and regulated by the FDA." Organon Inc. v. Teva

Pharms., Inc., 244 F. Supp. 2d 370, 379 (D.N.J. 2002). Indeed, at least one court has noted that

9

The new allegations in the SAC on this topic (as compared to what was in the
F AC) simply add some detail about the particular locations where Teva published these
statements about the "AB rating" (such as on its website or in materials produced by data
aggregators).
18

advertising a product as an "AB-rated bioequivalent" to a brand name drug is "the only realistic
way [for an entity like Teva] to market their product at all." Id.; see also (Tr. at 15-16).
Moreover, the FDA is the entity that has given meaning to the term "AB rated." And in the
Orange Book, the FDA has explained that meaning: if a drug (like Teva's generic carvedilol) is
"AB-rated" to COREG, then it is bioequivalent to COREG, and it is therapeutically equivalent to
COREG but only for the conditions or uses specified in the labelingfor Teva 's product. (D.I. 65,
ex. B at xiii, xiv; SAC at if 66)
So although GSK alleges that Teva is suggesting to third parties that its generic product
was ''therapeutically equivalent to and fully substitutable for" COREG, (SAC at if 62 (emphasis
added)), under the circumstances here, Teva's simple claim that its product is "AB-rated" to
COREG (again, ifthere were not anything more alleged) could not amount to meaningful
evidence in support of that claim. 10 If anything, where a section viii carve-out is utilized, a
generic manufacturer's statement that its product was "AB-rated" to a branded drug would
typically be, as a definitional matter, more akin to a statement that its drug was not "fully
substitutable" for the branded drug (e.g., not therapeutically equivalent for any use that was

10

Indeed, were this not the case, then the concept behind the utilization of a section
viii carve-out would seem to be frustrated. Any generic drug manufacturer who utilized such a
carve out, but nevertheless stated that its product was "AB-rated" to a branded drug product,
would be potentially liable to the branded patent-holder for infringement as to the carved-out
method of use. Cf AstraZeneca Pharms. LP v. Apotex Corp., 669 F.3d 1370, 1380 (Fed. Cir.
2012) ("AstraZeneca 2012") (finding the plaintiffs' argument that "Section viii [carve-outs] ...
ignore market realities because even if a generic drug is formally approved only for unpatented
uses, pharmacists and doctors will nonetheless substitute the generic for all indications once it
becomes available" to be ''unpersuasive" because that position would, "in practice[] vitiate" the
statute permitting such carve-outs "by enabling[] infringement claims [pursuant to 35 U.S.C. §
27l(e)(2)] despite the fact that [defendant's] Section viii statements and corresponding proposed
labeling explicitly and undisputedly carve out all patented indications for [the drug]").
19

carved out of the generic's label). 11
In so concluding, the Court acknowledges GSK's allegations, (see, e.g., SAC at if 67),

that despite the above-referenced meaning of an "AB rating," third parties would nevertheless see
Teva's statements about that rating and substitute Teva's generic drug for GSK's branded
version-without any concern for whether the generic drug label actually includes all of the
indications that are contained in the branded drug label. And GSK further alleges that "[ o]n
information and belief' Teva knew this, and that it intended to take advantage of this reality, by
promoting the "AB rating" so that this would come to pass. (Id.) But in the Court's view (again,
absent any other evidence that speaks to a generic manufacturer's intent), a finding in this context
that the promotion of an "AB rating" could amount to a plausible induced infringement claim
would go too far. It would rely too heavily on the mindset or misconceptions of third parties in
an attempt to ascribe wrongful intent to the alleged inducer. Cf Warner-Lambert Co., 316 F .3d
at 1364 ("[M]ere knowledge of possible infringement by others does not amount to inducement;
specific intent and action to induce infringement must be proven."). Perhaps if there were facts
pleaded in a section viii carve-out case stating that the alleged inducer affirmatively took other
actions to tell physicians or consumers that its product was "fully substitutable" for the branded
drug product (e.g., facts indicating that the generic's representatives used those very words when
describing how its product could be used as compared to the branded drug), that would be
different. Or perhaps the conclusion would be different in a case like this if the branded

11

Moreover, to the extent that Teva was (via its Product Catalog) pointing third
parties to the Orange Book in explaining where an "AB rating" comes from, (SAC at if 65; D.I.
65, ex. C), then Teva was directing the third parties to the very publication that would further
make the above-referenced distinctions clear.

20

manufacturer offered more than "information and belief' that the generic manufacturer's intent
was to engage in a concerted effort to prey upon these market-based misconceptions as to what
an "AB rating" means. But none of those kinds of allegations are in the SAC. 12
All of the above is to say that, if GSK's only allegations as to Teva's specific intent to
induce infringement related to Teva's promotion of its drug as "AB rated" to COREG, then the
Court would not find that GSK had made out a plausible claim of induced infringement in the
relevant time period. But this is not all that GSK pleaded in the SAC. 13
b.

The press releases

GSK also points to the two press releases (one from June 2004 and one from September

12

If the "AB-rating"-related allegations were all that GSK had here, then its induced
infringement claim for the pre-May 2011 time period would also not be saved by its further
allegations as to what Teva did not do in the relevant time period. That is, one of GSK's
allegations is that Teva did not affirmatively inform the public that its drug was only "AB-rated"
for hypertension and post-MI LVD (and that its drug was not "AB-rated" for COREG's CHFonly indication). (Tr. at 77, 80-81; see also SAC at ,-r 67) But the Federal Circuit has recently
rejected a similar line of argument in which the patentee suggested that the generic
manufacturer's label "needs to contain a 'clear statement' to show that it was avoiding [the
patented] indication." Takeda Pharms. U.S.A., Inc. v. West-Ward Pharm. Corp., 785 F.3d 625,
632 n.4 (Fed. Cir. 2015) (citation omitted). The Federal Circuit explained that such a
requirement would "turn[] the legal test on its head. [The patentee] needs to show that [the
generic manufacturer/defendant] took affirmative steps to induce, not affirmative steps to make
sure others avoid infringement." Id.
13

Below, the Court will set out why other allegations in the SAC help to make out a
plausible claim of induced infringement in the relevant time period. In light of that conclusion,
the Court does not agree with Teva that GSK's allegations regarding Teva's trumpeting of an
"AB rating" amount to a "theory" that "must be dismissed" or otherwise stricken from the SAC.
(Tr. at 17) Despite what is said above, it is possible that evidence ofTeva's marketing of its drug
as "AB rated" combined with the other facts alleged in the SAC (and other facts further
developed during discovery) could be a part of a winning induced infringement argument for
GSK. Again, the Court's point here is simply that if GSK's allegations regarding the "AB
rating" were all that it had, that could not be enough to withstand a motion to dismiss.
21

2007), identified in paragraphs 63 and 64 of the SAC, as further evidence ofTeva's specific
intent to target the entire market for carvedilol-including the treatment of CHF patients. (D.I.
69 at 10 n.5 & 11; Tr. at 53-58) Teva counters that the press releases are irrelevant to the
induced infringement inquiry, since they were published before the '000 patent issued. (D.I. 64 at
9-10; D.I. 70 at 7-8) The Court disagrees with Teva.

It is true, as Teva points out, (D.I. 70 at 8), that the Federal Circuit held in Nat 'l Presto
Indus., Inc. v. West Bend Co., 76 F.3d 1185, 1196 (Fed. Cir. 1996), that "the general rule is that

inducement of infringement under§ 271(b) does not lie when the acts of inducement occurred
before there existed a patent to be infringed." This was so even where the actor had knowledge
of a pending patent application and the intent that, as a direct result of its actions, there would be
direct infringement by others after the patent issues. Nat 'l Presto Indus., 76 F .3d at 1196. It is
notable, however, that in Nat 'l Presto Indus., all of the relevant acts took place before the patent
had issued; indeed, the patent issued on the very same day that the plaintiff filed suit against the
defendant alleging, inter alia, induced infringement. Id. at 1194. In contrast to the facts at issue
in Nat'! Presto Indus., where there are acts of inducement that continue after the issuance of a
patent, courts have indicated that acts occurring prior to the patent's issuance could still be
relevant to an induced infringement claim. See, e.g., L.A. Biomed. Research Inst. at HarborUCLA Med. Ctr. v. Eli Lilly & Co., Case No. LA CV13-08567 JAK (JCGx), 2014 WL

11241786, at *3 (C.D. Cal. May 12, 2014) (declining to dismiss an induced infringement claim
where culpable conduct began before the issuance of the patent because "the complaint contains
allegations of continued culpable conduct after the issuance of the patent"); CreAgri, Inc. v.
Pinnaclife Inc., Case No.: 5:11-CV-06635-LHK, 2013 WL 3958379, at *4-5 (N.D. Cal. July 29,

22

2013) ("The Court is not persuaded that [the defendant's] activities cannot support an inference
of intent simply because the activities began before the [asserted] [p]atent was issued. To the
extent [the defendant] continued these activities after the patent was issued, the continued
activities reflect an intent to infringe upon the [asserted] [p ]atent.").
These rulings make good sense. The question is whether a party had the intent to and did
encourage the wrongful act of patent infringement in the relevant time frame-after a patent has
issued. See Nat'! Presto Indus., 76 F.3d at 1194. And surely it seems possible that what the
party did and said before the patent issued might at least bear on what its mindset was in the
crucial post-issuance time period (so long as that party did, in fact, perform an inducing act in
that post-issuance time period). 14
In this case, as the Court will further discuss below, GSK has alleged acts of inducement
that occurred after the issuance of the '000 patent. And so, for example, as to the September
2007 press release, although it was sent out prior to the issuance of the '000 patent in January
2008, the document can still bear on Teva's intent to capture the CHF market after the patent
issued a few months later. That press release came at a time when Teva had amended its
proposed label in a stated attempt to carve out the CHF indication. Despite this, the press release
notes that COREG had annual sales of "approximately $1. 7 billion in the United States"-a sales
figure that undisputedly includes sales from the treatment of CHF patients. (SAC, ex. L; see also
id. at if 64; D.I. 69 at 11) It may be seen as a small piece of intent evidence in and of itself. But

it is nevertheless some evidence that can be used to make the case that Teva targeted the CHF

14

Indeed, when questioned further about this conclusion at oral argument, Teva's
counsel did not appear to dispute the rationale behind it. (See Tr. at 12-15)
23

market after January 2008 (and thus then intended to take aim at all of the $1. 7 billion in sales
opportunities that were referred to in the September 2007 press release). 15
2.

Contents of Teva's Label

GSK's SAC also points to another type of conduct that is said to be evidence of
inducement of infringement during the pre-May 2011 period: that relating to the content of and
promotion ofTeva's carved-out (or "skinny") label for its generic carvedilol tablets. Here, GSK
asserts that certain language in that label-language relating to the indication for treatment of
post-MI LVD-actually amounts to encouragement for doctors and patients to use Teva's drug to
infringe the '000 patent. (SAC

at~

28-30, 52) In other words, GSK is alleging that the FDA-

approved post-MI LVD indication is drafted in such a way that it "still included an indication to
reduce cardiovascular mortality in CHF patients who also suffered from [pJost-MILVD[,]"

such that "[b ]y including the [post-MI LVD] indication on its skinny label, Teva was knowingly
instructing and encouraging physicians to prescribe its generic carvedilol to patients, including
patients with CHF, for a period of more than six months to reduce the risk of mortality." (D.I. 69

at 4 (emphasis added)) 16 The specific portions ofTeva's skinny label that GSK highlights in

15

As for the June 2004 press release, Teva notes that it was not only disseminated
three and a half years prior to the issuance of the '000 patent, but it also was circulated at a very
different stage-at a point when Teva was clearly planning to include the CHF indication on its
label, because it had previously filed a Paragraph IV certification challenging the validity of the
'069 patent. (Tr. at 13-14) The Court understands, however, that GSK is pointing to the 2004
press release simply to underscore its claim that for many years, in one way or another, Teva had
designs on the CHF market for carvedilol. (See id. at 53-56) Therefore, the Court finds that it
could amount to a relevant piece of evidence as to an induced infringement claim.
16

It is fair to say that when GSK previously responded to Defendants' first motion
to dismiss, GSK did not highlight this particular argument then as a reason why dismissal was
inappropriate. (Tr. at 59) But the Court agrees with GSK that this should not preclude it from

24

making this argument are italicized below:
•

From the "Indications and Usage" section:

1.2

Left Ventricular Dysfunction Following Myocardial
Infarction
Carvedilol tablets are indicated to reduce cardiovascular mortality
in clinically stable patients who have survived the acute phase of a
myocardial infarction and have a left ventricular ejection fraction
of :-o;40% (with or without symptomatic heart failure).
•

From "Clinical Studies" section 14.2:
CAPRICORN was a double-blind study comparing carvedilol and
placebo in 1,959 patients with a recent myocardial infarction
(within 21 days) and left ventricular ejection fraction of :-o;40%,
with (47%) or without symptoms of heart failure.

•

From "Heart Failure/Fluid Retention" Section 5.4:
Worsening heart failure or fluid retention may occur during uptitration of carvedilol.

•

From "Patient Advice" section 17 .1:
Patients should consult their physicians if they experience signs or
symptoms of worsening heart failure such as weight gain or
increasing shortness of breath.

(SAC, ex. J (cited in SAC at if 52) (emphasis added))

relying on the argument now. Although GSK did not put the argument front and center in
responding to the prior motion, the factual basis to support the theory was at least present in the
F AC. (D.I. 124 at 1-2; see also D.I. 16 at if 26 & ex. G) And in responding to the prior motion
to dismiss, GSK did at times explain that there was overlap between the post-MI LVD patient
population and the CHF patient population that take carvedilol. (See D.I. 124) Thus, when the
Court ordered that GSK could amend its F AC to more fully plead additional facts showing why
Defendants induced infringement during the pre-May 2011 time period, it is understandable that
GSK would then set out additional facts relating to this theory in the SAC. (Id. at 2-3)
Therefore, the Court cannot find a reason why permitting GSK to press this theory now is unfair
to Teva.

25

Teva, however, argues to the contrary that GSK's theory cannot possibly amount to a
plausible claim of induced infringement. More specifically, Teva states that the Federal Circuit
has espoused the rule that "a generic drug's label cannot as a matter oflaw induce an allegedly
patented use if the generic drug is not approved for that use." (D.I. 70 at 1; see also D.I. 64 at 16;
Tr. at 29-30) In support ofthis argument, Teva relies heavily on the Federal Circuit's decisions
in three cases: Warner-Lambert Co. v. Apotex Corp., 316 F.3d 1348 (Fed. Cir. 2003), Allergan,

Inc. v. Alcon Labs, Inc., 324 F.3d 1322 (Fed Cir. 2003), and Bayer Schering Pharma AG v.
Lupin, Ltd., 676 F.3d 1316 (Fed. Cir. 2012). (D.I. 64 at 16-17) In these three ANDA cases, the
Federal Circuit held that the generic manufacturers' AND As could not form the basis of an
induced infringement claim pursuant to 35 U.S.C. § 271(e)(2) where they sought approval to
market generic forms of drugs for uses that were not covered by a valid patent. 17 Allergan, 324
F.3d at 1332-34; see also Bayer, 676 F.3d at 1319, 1326; Warner-Lambert Co., 316 F.3d at 1360,
1362. It is true (as GSK notes) that the patented uses at issue in those three cases were not
approved by the FDA, while here, COREG was FDA-approved for the patented use. ("GSK's
Presentation" Slides at 22-24); see Bayer, 676 F.3d at 1326; Warner-Lambert Co., 316 F.3d at
1353; Allergan, 324 F.3d at 1334. But the Federal Circuit has explained that this distinction
would not have made a difference in the outcomes of the three cases cited above:

17

Of course, while these were ANDA cases where the generic manufacturer had not
yet entered the market, once the generic drug does enter the market, the brand name companies
have the ability to sue for induced infringement under Section 271(b). See Astrazeneca Pharms.
LP, 2010 WL 5376310, at *14 (''If Plaintiffs believe that Defendants will induce doctors to
infringe the [relevant patents] upon approval of Defendants' ANDAs, they must assert a
'traditional' inducement claim under Section 271(b),[] not a claim under Section 271(e)(2)."),
aff'd, 669 F.3d 1370 (Fed. Cir. 2012). That is what has happened in this case.

26

[T]he [Hatch-Waxman] Act allows generic manufacturers to limit
the scope of regulatory approval they seek-and thereby forego
Paragraph IV certification and a [Section] 271(e)(2) infringement
suit-by excluding patented indications from their ANDAs. We
see no reason why those provisions would, on the one hand,
foreclose [Section] 271(e)(2) liability if an ANDA excludes a
patented but unapproved use as in Warner-Lambert, and yet, under
otherwise identical circumstances, allow [the brand drug company]
to pursue [Section] 271(e)(2) claims based on the patented, FDAapproved uses that were carved out in this case.
AstraZeneca 2012, 669 F.3d at 1379-80 (emphasis in original).
It could be, as GSK argues, that the results in these three ANDA cases can be

distinguished on the ground that there, there was no reasonable dispute that the patents-in-suit
"did not cover the uses of the drugs-in-suit described in the accused infringers' proposed labels."
(D.I. 69 at 13) 18 But what the three cases cannot stand for is the proposition that Teva puts
forward: that an induced infringement claim against a generic manufacturer can never be
successful if (1) the generic has attempted to utilize a section viii carve-out; (2) has asserted to
the FDA that in doing so, it is not seeking approval for a different, patented use for the drug; and
(3) the FDA permitted the generic to go to market with the carved-out label. This is made clear

18

See Bayer, 676 F.3d at 1320 (the asserted patent claimed a method of use
consisting of simultaneously achieving an anti-androgenic effect, and anti-aldosterone effect and
a contraceptive effect, while the use set forth in the "Indications and Usage" section of the
generics' proposed label was for the prevention of pregnancy in women who elect to use an oral
contraceptive); Allergan, 324 F. 3d at 1323-24, 1328 (explaining that the generics did not seek
FDA approval for the methods of using the drug at issue claimed in the asserted patents);
Warner-Lambert, 316 F.3d at 1354-55 (noting that the generic manufacturer submitted an ANDA
for approval to market a drug for a use not covered by an existing patent); see also AstraZeneca
2012, 669 F.3d at 1379-80 (noting that the brand name company has not alleged that the
generics' ANDAs seek FDA approval for uses ofrosuvastatin calcium covered by the asserted
patents and that the generics' proposed labeling "explicitly and undisputedly carve[d] out all
patented indications for rosuvastatin calcium").

27

by the Federal Circuit's holding in AstraZeneca LP v. Apotex, Inc., 633 F.3d 1042 (Fed. Cir.
2010).
In that case (referred to herein as "AstraZeneca 2010"), the FDA had approved the

plaintiffs' ("AstraZeneca") NDA for a budesonide inhalation suspension; the Orange Book entry
for AstraZeneca's product included a listing of the two AstraZeneca-owned patents-in-suit. See
AstraZeneca 2010, 633 F.3d at 1046. The two patents included method and product claims

directed to administering the drug once daily. Id. at 1046-4 7. AstraZeneca' s label for the drug,
however, indicated that the drug was approved for administration once or twice daily, that the
drug was available in three strengths (0.25 mg, 0.5 mg and 1.0 mg per 2 mL vial), and that it
shared a table of recommended starting doses based on patient history. Id. at 104 7. The label
also warned that patients should "'titrate down'" or "'downward-titrate'" to the "'lowest
effective dose"' of the medication, in order to avoid any adverse effects from excessive use of the
drug. Id. It was undisputed that the FDA required all manufacturers of the drug product to
include this downward-titration language in the labels of their products. Id.
The defendant ("Apotex") later submitted an ANDA seeking FDA approval to
manufacture and sell a generic version of the drug in question for twice-daily use-a type of use
that was clearly "not claimed in" the patents-in-suit. Id. Apotex's ANDA included a proposed
label for the generic drug that was identical to the branded label in most respects, but "would
contain no explicit mention of once-daily administration." Id. The label did, however, retain the
FDA-mandated downward-titration language that was in AstraZeneca's label, and the label
indicated that the generic drug would be available in only two strengths (0.25 mg and 0.5 mg per

28

2 mL vial). Id.
The day after Apotex's ANDA was approved, AstraZeneca initiated a declaratory
judgment action and moved for a preliminary injunction barring Apotex from distributing its
generic drug. Id. at 1047-48. Among AstraZeneca's claims was that the downward-titration
statements in Apotex's proposed label (e.g., "'it is desirable to downward-titrate to the lowest
effective dose once [the desired clinical effect] is achieved"') would effectively instruct
consumers to use the drug once daily such that it would induce infringement of the patents-insuit. Id. at 1048, 1057.
The district court agreed with AstraZeneca. Because the recommended starting dose for
certain patients was 0.5 mg daily administered twice daily in divided doses, the district court
reasoned that the first step in titrating down from such a dose would be to 0.25 mg once daily
(since there was no way of decreasing the amount of each dose below 0.25 mg). Id. at 1057. It
thus found that the "downward-titration language would necessarily lead patients to use a 0.25
mg vial of the drug once-daily." Id. The district court came to this conclusion even though: (1)
the FDA had previously issued a letter agreeing that the downward-titration language in Apotex's
ANDA did not teach once-daily use and was not protected by the patents-in-suit; and (2) the
FDA had required Apotex to include the downward-titration statements in its proposed label. Id.
at 1048, 1057-59.
The Federal Circuit affirmed the district court's conclusion in this regard. In doing so, it
noted that inducement of infringement requires evidence of'" active steps"' to encourage direct
infringement, and that such active steps could include "'advertising an infringing use or

29

instructing how to engage in an infringing use[.]'" Id. at 1059 (quoting Metro-Goldwyn-Mayer
Studios Inc. v. Grokster, Ltd., 545 U.S. 913, 936 (2005)); see also Takeda Pharms. US.A., Inc. v.
West-Ward Phann. Corp., 785 F.3d 625, 634 (Fed. Cir. 2015). The AstraZeneca 2010 Court

found that the "pertinent question is whether the proposed label instructs users to perform the
patented method[; ifit does, then] the proposed label may provide evidence of [a generic
manufacturer's] affirmative intent to induce infringement." 633 F.3d at 1060. The Federal
Circuit agreed that Apotex' s label provided such evidence, because it "would inevitably lead
some customers to practice the claimed method." Id. The AstraZeneca 2010 Court also relied on
the fact that there was evidence that Apotex knew that its "label presented infringement
problems" but that it utilized the label nonetheless. Id. at 1060-61. 19 The Federal Circuit's
decision was not impacted by the fact that Apotex had relied on the FDA's statements that the
downward-titration language did not teach once-daily use and was not protected by the patentsin-suit, since "the FDA is not the arbiter of patent infringement issues." Id. at 1061.
The decision in AstraZeneca 2010 indicates that there can, in fact, be situations where a
generic manufacturer seeks and obtains a section viii carve-out for a use of a drug that is
(according to the FDA) a "different" use from a patented use-and yet the generic's label could
nevertheless be written in such a way that it evidences active steps to induce patent infringement.

19

This evidence included the fact that (although Apotex strongly felt that its label
did not encourage infringement) after AstraZeneca expressed concern to Apotex about the label,
Apotex sent the FDA proposed amendments to the label. AstraZeneca 2010, 633 F.3d at 1058.
These proposed amendments further emphasized that Apotex was encouraging only twice-daily
use of the drug, not once-daily use. Id. at 1058-59. The FDA rejected those proposed changes.
Id.

30

See United Therapeutics Corp. v. Sandoz, Inc., Civil Action Nos. 12-CV-01617, 13-CV-316,
2014 WL 4259153, at *9, *14, *21 (D.N.J. Aug. 29, 2014) (explaining that an ANDA label that
actually instructs physicians to practice the patented method may constitute evidence of the
generic drug company's intent to induce physicians to engage in infringing conduct, even where a
generic company employed a section viii carve-out, but only if the "instructions [are] such that a
court can 'infer from those instructions an affirmative intent to infringe the patent"') (citation
omitted); cf L.A. Biomed. Research Inst., 2014 WL 11241786, at *5 (distinguishing WarnerLambert as a case where "the label itself did not give rise to any inference of inducement because
the alleged infringing use was umelated to the language on the label"). And that is exactly what
GSK argues happened here. GSK is asserting in the SAC that, despite "carving out" the CHF
indication, Teva's skinny label "still instructed and encouraged administering Teva's generic
carvedilol tablets long term (extending for more than six months unless terminated by unintended
adverse events) to decrease a risk of mortality caused by CHF"-an allegedly infringing use.
(SAC at ii 52; see also D.I. 69 at 13; Tr. at 65 ("[A]ll [of the above-italicized] instructions,
including the studies, and that parenthetical in [the post-MI LVD] indication, are relating to
patients with CHF and encouraging the physicians to treat their patients who have [post-MI
LVD] but are also symptomatic with CHF.")) In other words, the '000 patent "is alleged to cover
the use of carvedilol described in Teva's skinny label[.]" (DJ. 69 at 13; see also GSK's
Presentation Slide at 24)
Taking the decision in AstraZeneca 2010 into account, the Court agrees with GSK that it
is plausible that Teva's promotion of its skinny label encouraged infringement of the '000 patent

31

during the relevant time period. Most critically, the post-MI LVD indication in Section 1.2 of
Teva's label conveys that Teva's generic carvedilol tablets are indicated "to reduce
cardiovascular mortality in clinically stable patients ... with ... symptomatic heart failure."
(SAC at ii 52 & ex. J at Section 1.2) This excerpt from the post-MI LVD instruction is similar to
the carved-out CHF indication, which instructs that carvedilol tablets "are indicated for the

treatment ofmild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually
in addition to diuretics, ACE inhibitors and digitalis, to increase survival[.]" (Id., ex. F at
Section 1.1 (emphasis added)) In light of the similarity in the wording of the two indications
(along with the other language from Teva's label quoted in paragraph 52 of the SAC), it is
plausible that Teva's skinny label alone could "inevitably lead some consumers to practice the
claimed method." AstraZeneca 2010, 633 F.3d at 1060. 20
Indeed, in its briefing, Teva never really provided an argument as to why this conclusion
is an implausible one. (See D.I. 64, 70)21 At oral argument, the Court thus put this question to

20

As for Teva's argument that "[t]here is no allegation [in GSK's SAC] from which
this Court can reasonably infer that Teva knew that it was (allegedly) inducing infringement of
the '000 patent by including the [p]ost-MI LVD [indication] on its label[,]" (D.I. 64 at 18), the
Court does not agree. GSK alleges in the SAC that Teva knew about the '069 and '000 patents,
and that Teva generated its section viii carve-out label. (SAC at iMr 49, 50, 52, 71) From these
allegations, it is plausible that Teva knew that certain language in its label would induce
infringement of GSK' s patent directed to a method of decreasing mortality caused by CHF.
21

Instead, much ofTeva's briefing on this issue was focused on the argument that
treatingpost-MI LVD is not an infringing use of the '000 patent. (See, e.g., D.I. 64 at 14; D.I. 70
at 6) But at oral argument, even Teva's counsel acknowledged that GSK is not asserting that
''treatment of [post-MILVD] is, in and of itself, an infringing use." (Tr. at 20) Instead, what
GSK is alleging is that Teva knew of the '000 patent (as well as the original '069 patent), (SAC at
ii 71; see also D.I. 69 at 8), and that Teva knew that at least some of its generic carvedilol tablets
would be administered in an infringing manner because Teva's skinny label "instructed and

32

Teva's counsel-why was this an implausible theory? In response, Teva argued that the abovereferenced language in the skinny label that relates to heart failure is unproblematic, because (1)
"[Warner-Lambert, Allergan and Bayer] stand for the proposition that the label cannot induce

infringement of an indication for which the label has not been approved" and (2) no wording on
the label could induce infringement since "the two conditions [CHF and post-MI LVD] [indicate]
two completely different uses of the drug." (Tr. at 29-30; see also id. at 33)
The Court has above explained why it does not think the first of these two responses is a
sufficient answer-in that it does not believe that there exists any such hard-and-fast
"proposition" of the kind that Teva suggests. As for the second reason, it is true that the CHF
indication and the post-MILVD indication are two separate indications on GSK's COREG label.
But it is also true that the SAC alleges a clear relationship between the two conditions. In
describing GSK's motivation for seeking approval for COREG to be administered for the postMI LVD indication (following COREG's approval for treating CHF), the SAC alleges that there
were ''patients with CHF, or that were likely to develop CHF, that could not receive COREG®
because they recently experienced a myocardial infarction (i.e., a heart attack) and COREG® [at

one point] was not approved for use following a recent heart attack due, at least in part, to
concerns about worsening the patient's condition." (SAC

at~

28 (emphasis added)) According

to GSK, then, while these may be two different uses for carvedilol, they are not two completely
unrelated uses. Rather, post-MI LVD patients with CHF are a subset of CHF patients, and

encouraged physicians to administer carvedilol to [CHF] patients[,]" (D.I. 69 at 9 (emphasis
added)).

33

"[t]here's a very closely related synergy between these two and really [the post-MI LVD
indication] is sort of a special application of the CHF treatment." (Tr. at 62; see also SAC

at~

29 (explaining that a heart attack "can cause CHF" and that many patients in the CHAPS and
CAPRICORN studies, who had recently suffered a heart attack, "likely had CHF"); id.

at~

33

("Patients with LVD after a heart attack may also have signs of CHF, and many will eventually
develop CHF."); id.

at~

52 (stating that portions of Teva's skinny label note that certain patients

using Teva's product may experience symptoms of heart failure); Tr. at 51 (explaining that postMI LVD and CHF are "very intimately related"); id. at 68 (sarne)) 22 In fact, GSK asserts that the
post-MI LVD indication was only broken out as a separate indication because physicians were
concerned about giving CO REG to CHF patients who had just suffered heart attacks, and so
GSK "went out and had to do a separate study [] to alleviate the concerns of the doctors and the
FDA." (Tr. at 68-69)
For all of these reasons, the Court agrees that it is plausible that certain language in
Teva' s label could instruct the administration of carvedilol in order to decrease a risk of mortality
in patients surviving a heart attack with CHF. 23

22

At oral argument, Teva's counsel acknowledged that "there is admittedly overlap"
between the CHF and post-MI LVD patient groups. (Tr. at 25; see also id. at 86)
23

The facts with respect to Teva's label here are in contrast with those in a number
of cases (at various stages of the litigation process) where the branded drug company
unpersuasively pointed to the label as inducing infringement for carved out uses. See, e.g.,
Takeda Pharms. US.A., Inc. v. West-Ward Pharm. Corp., -F. Supp. 3d-, Civ. No. 14-1268SLR, 2016 WL 2904593, at *7 (D. Del. May 18, 2016) (finding that the generic's label, indicated
only for prophylaxis of gout flares, "is not a sufficient catalyst to constitute 'active steps taken to
encourage direct infringement'" of the branded drug company's patented uses of treating acute
gout flares, where the generic's label merely stated "'[i]f you have a gout flare while taking

34

3.

Lack of Alleged Substantial Non-infringing Uses for Carvedilol

There is one other set of allegations referenced in passing by GSK in responding to the
Motion, (D.I. 69 at 4), that the Court finds is relevant to the plausibility of the induced
infringement claim at issue. In its SAC, GSK alleges facts that plausibly suggest that: (1)
despite COREG's multiple approved indications, GSK has marketed the drug in the United
States only for the CHF indication; (2) uses of carvedilol tablets for the other two indications
(hypertension and post-MI LVD) are not substantial; and (3) Teva is aware that its generic
carvedilol tablets were not suitable for substantial non-infringing use. (See SAC at iii! 22, 32, 34,
52, 61; cf id. at if 83) Taken together and considered in the context of the other relevant
allegations (and in the light most favorable to GSK), the Court finds that these allegations can
further suggest Teva' s intent to induce use of its generic drug for the patented treatment of CHF
during the pre-May 2011 time period. (D.I. 69 at 4 ("All the while, Teva undoubtedly knew that

Mitigare, tell your healthcare provider"') (internal citations omitted); Otsuka Pharm. Co., Ltd. v.
Torrent Pharms. Ltd., Inc., 99 F. Supp. 3d 461, 486 (D.N.J. 2015) ("Critically, Otsuka does not
claim that any individual Defendant instructs and/or encourages the infringing use of its
aripiprazole product in either of the key sections of the package inserts: 'INDICATIONS AND
USAGE' or 'DOSAGE AND ADMINISTRATION."') (emphasis added); Acorda Therapeutics
Inc. v. Apotex Inc., Civil Action No. 07-4937 (GEB-MCA), 2011 WL 4074116, at *19 (D.N.J.
Sept. 6, 2011) (concluding that the generics' proposed labels failed to demonstrate specific intent
where there was "no explicit instruction to use the capsules with food to reduce somnolence" as
the court "is unwilling to infer intent based upon information that must be pieced together in a
puzzle"); Aventis Pharma Deutsch/and GmbH v. Cobalt Pharms., Inc., 355 F. Supp. 2d 586, 599
(D. Mass. 2005) (rejecting the patentee's active inducement claim where the plaintiff argued that
the "Warnings" and "Precautions" sections of the generic company's proposed labeling contained
information intended to encourage doctors to prescribe the drug at issue for the patented use of
treating heart failure, but the labeling actually appeared to discourage doctors from prescribing
the drug for patients with congestive heart failure).

35

COREG® was until that time administered almost exclusively, if not entirely, to reduce the risk
of mortality caused by CHF-the only use GSK actively promoted for years.") (citation omitted))
By way of further explanation, in Warner-Lambert the Federal Circuit rejected the brand
name manufacturer's induced infringement claim against a generic manufacturer who sought
approval to market a drug for non-patented uses. In that case, the drug at issue had many uses,
and only a small fraction of the prescriptions written for the drug were for the patented
indication. Warner-Lambert, 316 F.3d at 1365. This fact was particularly relevant to the
Warner-Lambert Court, as it explained that:

Especially where a product has substantial noninfringing uses,
intent to induce infringement cannot be inferred even when the
defendant has actual knowledge that some users of its product may
be infringing the patent. Where there are many uses for a product,
as the record reflects to be true of gabapentin, and fewer than 1 in
46 sales of that product are for infringing uses, we are not in a
position to infer or not infer intent on the part of [the generic]
without any direct evidence.
Id. 24 In other words, the magnitude of the substantial non-infringing uses for the drug prevented

24

See also Otsuka, 99 F. Supp. 3d at 495 (stating that "in the event a product has
substantial noninfringing uses, the Court cannot infer intent to induce infringement, even if these
Defendants had 'actual knowledge' that some of their products would infringe the [asserted]
patent") (quoting Warner-Lambert, 316 F.3d at 1365); Takeda Pharms. USA, Inc. v. West-Ward
Pharm. Corp., 72 F. Supp. 3d 539, 545 (D. Del. 2014) (noting that the use of the drug for the
non-patented indication was "substantial" and "[t]herefore, specific intent [to induce
infringement] cannot be inferred from the knowledge (actual or based on 'market realities'[]) that
a generic product may be used in infringing ways. There must instead be affirmative evidence of
specific intent and action to induce infringement."), aff'd, 785 F.3d 625 (Fed. Cir. 2015); Acorda
Therapeutics Inc., 2011 WL 4074116, at *19 (noting that where 75% of prescriptions for the
drug at issue were not for the patented indication, and therefore it was likely a "large portion of
[the generic's] capsules that are so prescribed do not infringe the patent. ... [then] it makes little
sense for [the generic's] intent to be to infringe the patent rather than to sell a commodity where
the vast majority of sales are non-infringing"); Organon, 244 F. Supp. 2d at 382 (granting

36

an inference of intent to induce infringement on the part of the generic manufacturer. To the
Court, this suggests that the converse is true as well-that where a brand name drug is alleged to

not have substantial noninfringing uses, it could be inferred that a generic company's knowledge
that some users of its product may be infringing the patent, (see SAC at iJ 73 ), evidences intent to
induce infringement.

4.

Conclusion

Taking all of the above together, the SAC alleges that Teva has taken specific acts to
induce infringement in the pre-May 2011 time period by disseminating its skinny label, the
contents of which could instruct third parties to infringe the '000 patent. Moreover, GSK has
alleged at least some other facts that (read in the light most favorable to it) paint Teva as an entity
that: (1) had been long planning to encourage this infringing use of carvedilol; and (2) would
have significant financial incentive to do so, since the amount of non-infringing uses of the drug
are minimal. In the Court's view, these pleaded facts are enough to allege a plausible induced
infringement claim in the relevant time period. Twombly, 550 U.S. at 570; cf Acorda

Therapeutics Inc. v. Apotex Inc., Civil Action No. 07-4937 (GEB-MCA), 2011 WL 4074116, at
*16 (D.N.J. Sept. 6, 2011) (explaining in an opinion following a bench trial that whether the
court can appropriately make an inference of specific intent based on instructions in a drug label
"depends on how explicitly the instructions suggest the infringement, any direct evidence, the

summary judgment of no induced infringement where the plaintiff failed to meet its burden of
adducing facts sufficient to prove that the generic manufacturers acted or will act with the intent
to induce infringement where, inter alia, "there is a significant market for non-infringing uses of
[the drug at issue]").

37

[c]ourt's fact-finding conclusions and the surrounding circumstances"). 25
IV.

CONCLUSION

25

With all of this said, this conclusion is not the same as a determination that GSK
will ultimately be able to prove its induced infringement claim as to the pre-May 2011 time
period. See In re Burlington Coat Factory Sec. Litig., 114 F.3d at 1420 ('"The issue is not
whether [GSK] will ultimately prevail but whether [GSK] is entitled to offer evidence to support
the claims.'") (citation omitted). Teva, for example, has pointed to some possible challenges that
GSK faces in proving the claim.
For one thing, it is not clear on this record why, although GSK "[a]bsolutely" wrote the
content of the post-MI LVD indication of its label intending to encourage the use of COREG for
congestive heart failure, (Tr. at 73), GSK did not submit a use code for purposes of the Orange
Book indicating that the '000 patent covered the post-MILVD indication, (SAC at if 40). Patent
owners list patents along with use codes in the Orange Book in order to give notice to the FDA
and generic companies of patents and their corresponding uses upon which the patentee could
reasonably bring suit. See Organon, 244 F. Supp. 2d at 374 n.6; see also Allergan, 324 F. 3d at
1339 (explaining that "the general purpose of the Patent Listing Provision[] is to give notice to a
potential infringer (direct or induced) of patents upon which the patentee could reasonably bring
a suit"). The Federal Circuit has noted that these provisions "encourage broad disclosure"-"the
category of claims as to which infringement could reasonably be asserted is plainly broader than
the category of claims that are infringed." Bayer, 676 F.3d at 1325.
Additionally, the Court notes that while the patented method of use calls for the
administration of carvedilol, inter alia, "in conjunction with one or more other therapeutic
agents, said agents being selected from the group consisting of an angiotensin converting enzyme
inhibitor (ACE), a diuretic, and digoxin[,]" ('000 patent, col. 8:33-35), the post-MILVD
indication in Teva's label does not mention any such therapeutic agents, (SAC, ex. J at Section
1.2). Meanwhile, the CHF indication on COREG's label does reference the administration of the
drug ''usually in addition to diuretics, ACE inhibitors, and digitalis[.]" (Id., ex. F at Section 1.1)
However, the Court does note that at least the "Heart Failure/Fluid Retention" section ofTeva's
skinny label states that if"[ w ]orsening heart failure" occurs during up-titration, "diuretics should
be increased[.]" (Id., ex. J at Section 5.4; see also id. at "Patient Information"-"What are
carvedilol tablets?" section (noting that "Carvedilol tablets are used, often with other medicines .
. . [t]o treat patients who had a heart attack that worsened how well the heart pumps")) In light
of this, and because this issue was not really a focal point of the parties' Motion-related
arguments, the Court cannot conclude that it is implausible that Teva's label instructs physicians
to utilize this portion of the patented method. But the issue may be one, among others, that Teva
raises again at the proof stage.

38

For the foregoing reasons, the Court recommends that Teva's Motion be DENIED.
This Report and Recommendation is filed pursuant to 28 U.S.C. § 636(b)(l)(B), Fed. R.
Civ. P. 72(b)(l), and D. Del. LR 72.1. The parties may serve and file specific written objections
within fourteen ( 14) days after being served with a copy of this Report and Recommendation.
Fed. R. Civ. P. 72(b ). The failure of a party to object to legal conclusions may result in the loss
of the right to de novo review in the district court. See Henderson v. Carlson, 812 F.2d 874, 87879 (3d Cir. 1987); Sincavage v. Barnhart, 171 F. App'x 924, 925 n.1 (3d Cir. 2006).
The parties are directed to the Court's Standing Order for Objections Filed Under Fed. R.
Civ. P. 72, dated October 9, 2013, a copy of which is available on the District Court's website,
located at http://www.ded.uscourts.gov.

Dated: July 20, 2016
Christopher J. Burke
UNITED STATES MAGISTRATE JUDGE

39